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Abstract 
 
Giant congenital nevi are associated with clinical complications such as neurocutaneous 
melanosis and melanoma. Virtually nothing is known about why some individuals develop these 
lesions. We previously identified the sonic hedgehog (Shh) pathway regulator Cdon as a 
candidate nevus modifier gene. Here we validate this by studying Cdon knockout mice, and go 
on to establishment the mechanism by which Shh exacerbates nevogenesis. Cdon knockout 
mice develop blue nevi without the need for somatic melanocyte oncogenic mutation. In a 
mouse model carrying melanocyte NRASQ61K we found that strain backgrounds that carry 
genetic variants that cause increased keratinocyte Shh pathway activity, as measured by Gli1 
and Gli2 expression, develop giant congenital nevi. Shh components are also active adjacent to 
human congenital nevi. Mechanistically, this exacerbation of nevogenesis is driven via the 
release of the melanocyte mitogen endothelin-1 from keratinocytes. We then suppressed nevus 
development in mice using Shh and endothelin antagonists. Our work suggests a novel aspect 
of nevus development whereby keratinocyte cytokines such as endothelin-1 can exacerbate 
nevogenesis, and provides potential therapeutic approaches for giant congenital nevi. Further, it 
highlights the notion that germline genetic variation, in addition to somatic melanocyte mutation, 
can strongly influence the histopathological features of melanocytic nevi. 
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Introduction 
The presence of multiple nevi is the strongest risk factor for development of melanoma (Gandini 
et al, 2005). Whereas common acquired nevi emanate from the dermo-epithelial junction of the 
skin, many nevi are dermal or have a dermal component. Congenital nevi are mostly dermal, 
and observed at birth or in the very young (Sowa et al, 2008; Price et al, 2010). They may be 
small birthmarks anywhere on the body, large lesions mostly on the head and neck, or giant 
lesions sometimes covering large areas of body. The latter have an increased risk for 
transformation melanoma (Zaal et al., 2004). Some patients develop neural melanosis, which 
carries a poor prognosis, with no effective treatment (Flores-Sarnat et al, 2013). One way to 
approach understanding the formation of these lesions is to look for natural gene variation that 
confers susceptibility to their development. But in terms of germline gene variation there are no 
GWAS or genetic association studies conducted on human giant congenital nevi patients, nor 
familial studies that might reveal rare mutations 
Congenital nevi probably derive from melanocytes that have escaped the developmental 
route from the neural crest to the skin, and become trapped in the dermis, where they 
proliferate. Many transgenic mice carrying melanocyte-specific oncogenic mutations develop 
dermal melanocytic proliferations reminiscent of giant congenital nevi (Shakhova et al, 2012; 
Pawlikowski et al, 2015). Transgenic Cdk4R24C::Tyr-NRASQ61K (hereafter termed Cdk4::NRAS) 
mice begin to develop dermal nevi during the second week after birth (Chai et al., 2014; 
Chitsazan et al, 2016). Since the corresponding developmental period in which embryonic 
melanocytes have mostly migrated to the hair bulb is pre-natal in humans, beginning at around 
18 weeks (Gleason et al, 2008), and examination of aborted foetuses at this stage have 
indicated the presence of deep dermal nevi at this stage (Cramer and Fesyuk, 2012), one might 
expect that the mechanisms promoting escape of melanocytes from the hair follicle to the 
dermis should be similar in both species. Hence in order to discover genes affecting congenital 
nevogenesis, we utilised the Collaborative Cross (CC) (Morahan et al, 2008; Welsh et al, 2014), 
a resource of characterised mouse strains, in conjunction with the Cdk4:;NRAS model,  to 
identify a quantitative trait locus (QTL) on mouse chromosome 9 (Chitsazan et al, 2016) 
influencing nevocyte density. Examination of the founder haplotype coefficients through the 
linked interval on chromosome 9 showed that the nevus-susceptible strains carried the causal 
variant derived from the NOD/LtJ founder (hereafter termed NOD). One of the best candidates 
in this QTL was Cdon, a sonic hedgehog (Shh) pathway regulator, which when knocked out in 
zebrafish results in hyperpigmentation of the dorsal surface (Powell et al, 2015). Shh signalling 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 | P a g e  
 
is controlled by dependence receptors Cdon and Ptch1 (Delloye-Bourgeois et al, 2013). Their 
inactivation by Shh removes the inhibition on smoothened (Smo), a positive regulator of Gli 
transcription factors (Ruiz Altaba, 1997; Taipale et al, 2002; Oro and Higgins, 2003; 
Ouspenskaia et al, 2016, Brownell et al, 2011). Deregulation of the SHH pathway drives the 
formation of the keratinocyte-derived skin cancer, basal cell carcinoma (BCC), which are 
sometimes pigmented. Here we define a cell extrinsic role for the Shh-endothelin1 axis in the 
development of giant congenital nevi. 
Results 
Genetic Background Dictates the Histopathology of Melanocytic Hyperplasia 
Cdk4::NRAS mice develop dermal nevi by postnatal day 10, from melanocytes escaping the 
hair follicles (Chitsazan et al, 2016). Cdk4R24C/R24C::Tyr-NRASQ61K/+ males were bred with 
females from many CC strains to generate progeny heterozygous for Cdk4 and NRAS 
transgenes. Dorsal skin was collected from >3 progeny of each CC cross, and the density of 
dermal nevocytes scored from 1 (least dense) to 10 (most dense). The method of scoring each 
strain for nevus cell density in the dermis is described in Chitsazan et al. (2016). Here we went 
on to diagnose lesions at each density level according to histopathological criteria for 
diagnosing human melanocytic hyperplasia. Those with a score of 1-4 were best defined as 
superficial or deep blue nevi (Figure 1a; Figure S1), a score of 5-6 as deep penetrating nevi, 7 
as epitheloid blue nevus, and 8-10 as melanocytoma (Gavriilidis et al, 2013, Zembowicz and 
Scolyer, 2011). The nevus density score was closely related to depth and histopathological 
diagnosis (Figure 1b). In general a particular histopathological parameter may be shared by 
more than one lesion subtype, and we observed a gradation of nevocyte density scores closely, 
but not perfectly, reflecting nevus subtype (Figures 1c). Despite all mice carrying a melanocyte 
NRASQ61K mutation making them susceptible to the development of nevi, germ-line genetic 
variation dramatically alters nevus histopathological presentation.  
 
Validation of a candidate Modifier Gene for Nevus Exacerbation  
Previously we identified Cdon as candidate nevus modifier gene by studying Cdk4::NRAS mice 
crossed onto many CC strain backgrounds (Chitsazan et al, 2016). We used heterozygous loss 
of Cdon, since homozygous loss is embryonic lethal (Cole and Kraus, 2003). Cdon+/- mice (n=4), 
and not littermate wild type controls (n=3), developed blue nevi in old age. Dermoscopy of the 
lesions showed a blue hue suggesting nevocyte location in the deep dermis (Figure 2a). 
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Dendritic and epithelioid melanocytes were present. We also noted the presence of pigmented 
melanocytes in the telogen bulge region that were not present in wt mice (Figure 2b). Of note, 
these aged Cdon+/- mice had fewer hair follicles than controls (Figure S4). The differences in 
hair follicle number are unsurprising given the pivotal role of Shh in hair follicle homeostasis 
(Sato et al, 1999). Cdon+/- mice develop dermal nevi without the need for somatic BRAF or 
NRAS mutation in melanocytes.  
We then assessed the visual appearance of Cdk4::NRAS mice carrying the CdonNOD 
allele (Figure 2c), versus controls carrying the non-NOD allele (by genotyping the CdonP456S 
mutation). Both cohorts were hyperpigmented, but susceptible mice carrying CdonNOD 
developed leathery thickenings reminiscent of giant congenital nevi. Dermoscopy of the tail and 
dorsal skin of resistant mice showed a scattered blue hue on a white background with some 
small superficial and deep nodules, whereas in the susceptible mice carrying CdonNOD both the 
deeper nevi and nodules were much larger (Figure 2c). Histologically, the former were blue 
nevi, while the latter consisted of strings interconnected melanocytomas producing a 
macroscopic appearance of giant congenital nevus. The formation of leathery lesions can be 
observed in patients with medium-sized or giant congenital nevi (Figure 2d). The human and 
murine giant congenital nevi lesions showed other similarities including generalised 
hyperpigmentation, some large plaques, and ectopic hair growth (hypertrichosis). lnactivation of 
the Shh pathway in mouse keratinocytes, in conjunction with melanocyte NRASQ61K mutation, 
produced large leathery melanocytic plaques reminiscent of human giant congenital nevi. Thus, 
while we do not know that status of the SHH pathway in such individuals, upregulated 
keratinocyte SHH and EDN1 might be one potential mechanism.  
 
In vivo Activation of Shh Signaling in Cdk4::NRAS Mice with Giant Congenital Nevi  
To confirm activation of the Shh pathway in strains carrying the CdonNOD variant we stained the 
mouse skin for Gli1 and Gli2, markers of Shh activation, using multiplexed immunofluorescence 
(IF) staining with Tyramide-based amplification (Figure 3). We stained dorsal skin from 
Cdk4::NRAS mice with Sox10 (a melanocyte maker) and Gli1 and Gli2 antibodies, to examine 
protein expression in the vicinity of the early nevi (mice at P10 and P21), and melanocytoma (in 
adult mice). In CdonNOD strains, at P10, when nevi are beginning to form, Gli proteins were 
mostly expressed in the hair follicle (Figure 3a). In contrast, in the skin of resistant strains there 
was low levels Gli expression at P10 (Figures 3b), which was confirmed by quantitating the 
proportion of Gli1 and Gli2 positive cells in the skin using InForm software (Figures 3e, and 3f). 
Likewise, in susceptible adult mice with follicles in telogen, Gli1 and Gli2 were expressed in a 
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much higher proportion of cells within the skin than in resistant CC mouse strains (Figure 3c, d. 
e, f).  
In human skin, CDON is expressed mainly in the suprabasal epidermis, and in parts of 
the hair follicle (Figure S2). In mouse skin also Cdon is expressed in the epidermis and the hair 
follicle. We stained four human intradermal nevi (Figure 3g and S3a) with congenital features 
including deep extension into the reticular dermis, and peri-appendageal accentuation. CDON 
was mostly expressed in differentiated keratinocytes in upper epidermis, and in the hair follicle. 
The expression of GLIs in keratinocytes is consistent with a role for activated SHH in 
exacerbating human dermal nevus development. In the mouse this effect largely influences the 
early stages of nevus formation, which occur prenatally in humans. Understanding the temporal 
development (beginning at ~ 10 days of age), and the skin compartment in which they are first 
observed (in the superficial dermis adjacent to hair follicles) in our mouse model, provides us 
with a unique opportunity to better study the mechanisms by which natural genetic variation 
influences congenital nevi formation.  
 
Linking Keratinocyte Shh Signalling to Development of Dermal Nevi 
LDE225, a potent antagonist of the Shh pathway protein Smo, is an FDA-approved drug for 
topical treatment of BCC (Skvara et al, 2011). We administered this topically in DMSO to the 
dorsal skin every day from P5 to P10. Skin samples harvested at the end of P10 from drug-
treated and control groups were stained for Sox10 (Figure 3h). Whereas at P10 small groups of 
melanocytes (early nevi) were beginning to form in the control mice, these were not evident in 
the drug-treated animals. The proportion of Sox10 positive nuclei in the dorsal skin of LDE225-
treated mice was significantly lower in the superficial dermis than in controls (Figure 3i). The 
drug treatment also suppressed melanocyte numbers in the hair bulb suggesting that less 
melanocytes may be escaping from it (Figure 3i). Thus, drug targeting of Shh pathway activity 
can significantly suppress nevus formation.  
 
Shh-Edn1 Axis Exacerbates Nevogenesis 
Basal cell carcinomas in humans and mice are sometimes pigmented (Chow et al, 2011; 
Grachtchouk et al, 2003; Moore and Bennett, 2012; Peterson et al, 2015). In mice with 
keratinocyte-specific inactivation of Ptch1 (Peterson et al, 2015), or activation of other Shh 
pathway components e.g. Smo (Grachtchouk et al, 2003), Gli2 (Grachtchouk et al, 2000), and 
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Shh (Ellis et al, 2003), hyperpigmentation is usually evident as pigmented melanocytes within or 
near BCCs. These transgenics were all generated to study BCC hence the hyperpigmentation 
phenotypes were generally not described. Where hyperpigmented skin was reported, and 
adequate published images available, the lesions appeared to be blue nevi (Ellis et al, 2003), 
which also develop in the Cdon+/- mice.  
We set out to ask which genes that influence melanocyte behaviour are over-expressed in the 
skin of these transgenics? We compared gene expression from RNA sequencing of Ptch1 
knockout epidermis to that of controls. For additional confirmation we used published data from 
another mouse BCC model (Youssef et al, 2012). In this case YFP-positive keratinocytes were 
isolated from tamoxifen-treated and control K14-CreER::Rosa-Smo2 (K14-Smo2) mice, and 
microarray gene expression analysis performed. In both cases Shh target genes are up-
regulated in keratinocytes e.g. Gli1, Gli2, Ptch1 (Figure 4a). Given that transgenic over-
expression of known melanocyte mitogens like hepatocyte growth factor (Hgf), endothelin 3 
(Edn3), in murine keratinocytes induces similar melanocytic dermal lesions to that we see in our 
model (Aoki et al., 2009), we looked for up-regulation of genes encoding secreted cytokines 
known to be melanocyte mitogens; Edn1, Edn2, Edn3, Hgf, Fgf, Pomc (αMsh and Acth), and 
Ngf (Hirobe, 2005), and Wnt5a and Wnt7b (Figure 4a). Edn1 (endothelin 1) (Zhang et al, 2013; 
Hyter et al, 2013; Urtatiz et al, 2016; Chiriboga et al, 2016) was the only such gene statistically 
upregulated in both the Ptch1 and Smo mouse model epidermis. By IF staining of mouse dorsal 
skin we found that Edn1 is expressed in the epidermis and certain cells in the outer root sheath 
and hair bulb (Figure 4b). We quantitated the expression of Edn1 protein in susceptible and 
resistant strains at P10. The number of positive cells per mm2 was significantly higher in the 
susceptible strains (Figure 4c), suggesting that Edn1 secretion is a plausible mechanism for 
exacerbation of nevogenesis. We then compared Edn1 expression in WT and aged Cdon+/- mice 
with hair follicles in telogen (Figure 4d). Quantitation of the proportion of cells positive for Edn1 
showed that the Cdon+/-  mice express more of this cytokine than wild type mice (Figure 4e). To 
confirm the functional effect of Edn1 in exacerbating nevogenesis, we utilized an inhibitor of the 
Edn1 receptor, Bosentan. Daily treatments of Cdk4-NRAS mice (from P5 to P10 
intraperitoneally and topically) with Bosentan significantly reduced the appearance of blue nevi 
in the superficial dermis (Figures 4f and 4g), and the hair follicle (Figure 4f and 4h).  
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Discussion 
Although NRASQ61K mutation is the major somatic mutation carried in giant congenital 
nevi, virtually nothing else is known about the mechanism of formation of these lesions. Despite 
the evolutionary differences in the pigmentary system between species (mouse melanocytes 
are usually limited to hair follicles whereas in humans they are also in the epidermis), virtually all 
genes involved in regulating mouse melanocyte behaviour (i.e. pigmentation) are relevant in 
humans (Walker et al, 2011). Given that we have gone to great lengths to diagnose the murine 
nevi precisely according to the histopathological criteria used for human nevi, and shown that 
the pathway we have discovered is active in the epidermis adjacent to human congenital nevi, 
the cell extrinsic mechanism we have delineated could be involved in the formation of human 
nevi. It is not known whether germline CDON variants influence the development of human 
congenital nevi, but our findings enable us to postulate that variants in any gene that results in 
up-regulation of a pathway that increases expression of a secreted keratinocyte cytokine that is 
a melanocyte mitogen, could be a candidate.  
A role for paracrine Edn1 driving nevogenesis seems uncontroversial. It is a mitogen for 
human melanocytes in culture (Imokawa et al., 1992) and in human skin explants (Takeo et al., 
2016), and is involved in wound-induced melanocyte activation (Park et al, 2015). Edn1, along 
with Edn2 and Edn3, are mostly active only in anagen, or growth phase of the hair cycle, when 
they assist either to activate melanocyte stem cells, and/or to assist in migration of melanocytes 
to the hair bulb (Rabbani et al, 2011; Takeo et al, 2016; Mort et al, 2015). Hence under stress 
such as increased endothelin secretion or the presence of a NRAS or BRAF mutation it is 
unsurprising that melanocytes escape their follicular niches and congregate in the dermis as 
nevi. Edn1 binds to the melanocyte Ednrb receptor and stimulates signalling through 
Gnaq/Gna11 and subsequently the MAPK pathway (Figure 5). GNAQ is somatically mutated in 
~80% of human blue nevi, suggesting that signalling through it is important in dermal nevus 
development, and mice expressing an activated Gnaq mutant in their melanocytes exhibit 
essentially the same phenotype in terms of dermal melanocytic nevi that we observe in our 
model with activated keratinocyte Shh (Huang et al., 2015). Perhaps SHH-EDN1 signalling acts 
as a rheostat, via melanocyte EDN1-GNAQ-MAPK, in exacerbating blue nevi to form very large 
or giant nevi (Figure 5).  
SHH is normally associated with BCC. PTCH1 is frequently mutated in BCC-prone 
patients, and the SHH pathway is mutated somatically in BCC (Tang et al., 2010; Briscoe and 
Therond, 2013). Notably, the mouse strains carrying the CdonNOD variant do not develop BCC, 
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presumably since the associated keratinocyte Shh up-regulation is relatively subtle. But one 
would expect BCCs to be pigmented, and many are, with melanocytes unusually located around 
the edges or within the lesion. EDN1 is highly expressed adjacent pigmented, but not non-
pigmented human BCCs (Lan et al, 2005). Since 80% of Asian, but only 3% of Caucasian BCCs 
(Moore and Bennett, 2012; Chow et al, 2011), it is likely that modifier alleles that differ between 
these ethnic backgrounds modulate the SHH-EDN1 axis. However murine models with 
keratinocyte-specific deregulation of Shh components e.g. Shh (Ellis et al, 2003), Ptch1 
(Peterson et al, 2015), Smo (Grachtchouk et al, 2003) and Gli2 (Grachtchouk et al, 2000), all 
exhibit melanocyte hyperplasia.  
An important message is the notion that different genes act at different stages of tumor 
progression. We show (Figure 1c) that the strains carrying the CdonNOD allele and upregulated 
keratinocyte Shh components are not necessarily more prone to the development of melanoma, 
although the nevi are much larger. Since the transformation of an individual nevus (of which 
there are >10,000 per mouse on an FVB strain background) is extremely low (a 0.04% 
probability that a nevus will convert to melanoma; Chai et al, 2014), it must be modified by 
epigenetic, or other genetic background effects that are yet been elucidated.  
Our strategy using mouse models could be helpful in gaining insights into genetic 
background influences in other rare diseases. Giant congenital nevi are only seen in about 
1/20,000 births, and no genetic studies have been performed on large case-control cohorts. But 
they can be disfiguring, covering significant parts of the body surface, and with a high propensity 
to convert to melanoma. They are not always stable. Satellite lesions can form, and neural 
melanosis sometimes becomes manifest in these patients. Studying human lesions post-natally 
does not tell us how they are formed. In years to come germ-line DNA from large enough 
cohorts may become available for genome wide association studies into susceptibility. But not 
being a common disease it will be difficult to attract traditional research funding. To confirm our 
hypothesis that keratinocyte cytokines may feed the formation of giant nevi would entail 
sensitive gene expression and or immunohistochemical studies of representative skin samples 
from perhaps hundreds of patients and ethnic matched controls, again a difficult study to realize.  
Targeting keratinocyte cytokines might provide hope for a drug therapy by which giant 
nevi could be controlled, or even reversed, since they can spontaneously regress (Arpaia et al, 
2005; Nath et al, 2011; Cusak et al, 2009). Surgical excision is the gold standard treatment for 
most cutaneous tumours. But topical treatments are now available for solar keratosis and in situ 
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squamous and basal cell carcinomas (e.g. fluorouracil, imiquimod, Picato gels), lesions 
previously only removed by excision. The same may eventually be true for large/giant nevi. 
Topical treatment of pigmented BCCs with the SMO antagonist LDE225, and Bosentan an 
inhibitor of Edn signalling, which we used in our study to suppress the development of dermal 
nevi, results in the disappearance of the associated melanocytosis.  
 
Methods 
Mice and Phenotyping 
Mouse breeding and screening for nevus density modifier gene: By breeding Cdk4R24C/R24C::Tyr-
NRASQ61K/+ males with females from 70 CC strains. Experiments were undertaken with institute 
animal ethics approval (A98004M). Cdon knockout mice were kindly provided by Robert S. 
Krauss (Icahn School of Medicine at Mount Sinai, NY). Collaborative Cross mouse strains were 
provided by Grant Morahan (Harry Perkins Institute of Medical Research, Perth). By breeding 
Cdk4R24C/R24C::Tyr-NRASQ61K/+ males (FVB background) with CC females we generated progeny 
heterozygous for Cdk4 and NRAS (Chitsazan 2016). At P10 small nests of melanocytic cells 
(nevi) appear within the superficial dermis around hair follicles (Chai et al, 2013). Nevi are 
completely formed by P40.  
Human study 
Experiments were undertaken with the University of Queensland Human Research Ethics 
Committee A & B approval (approval number 2011001201/HREC/11/QPAH/363).  
RNA Sequencing 
Four weeks after tamoxifen injection, epidermal cells of K14-CreER::Ptch1fl/fl and control mice 
were recovered by digestion and flow sorting of EPCAM+ epidermal cells. RNA was isolated 
using RNeasy Kit and libraries generated with Illumina mRNA kit. Sequencing 
was performed using Ilumina HiSeq chemistry, with 50bp single reads. The RNA-seq samples 
were mapped to mouse genome MM10 using TopHat2, then mapped reads for each gene 
counted for every sample using HT-Seq. We used EdgeR and DEseq to estimate the 
significance of differential expression between groups. 
Haematoxylin and Eosin Staining Protocol 
Slides from formalin-fixed paraffin-embedded blocks were dewaxed and stained with 
haematoxylin and eosin using Leica autostainer XL. 
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Dermoscopy of Mouse Skin 
After shaving to remove hair, clinical images were acquired with a digital camera (Canon 
PowerShot G10; Canon, Tokyo, Japan). Detailed macroscopic images were acquired with the 
same camera equipped with a dermoscopic attachment (Dermlite©, 3Gen, USA). 
Multiplexed Fluorescent Immunohistochemistry with Tyramide Signal Amplification 
Sections from paraffin-embedded lesions were dewaxed and treated with Dako low pH antigen 
retrieval solution at 1000C for 15 minutes. Endogenous peroxidase activity was quenched in 3% 
H2O2, and sections blocked with 5% bovine serum albumin. Primary Sox10 (sc-17342), Gli1 
(ab151796), Gli2 (AF3635), Cdon (sc-134837) and Edn1 (ab117757) antibodies were applied, 
followed by the appropriate secondary antibodies. After washing, the signal was amplified using 
Perkin Elmer Tyramide amplificiation kit (FITC, CY3, CY3.5, CY5), slides were washed, 
counterstained with DAPI, and coverslipped using DAKO mounting medium. Slides were 
scanned using the Vectra spectral imaging system (PerkinElmer). Images were scanned at at 
4X magnification. Multispectral images (MSI) were captured using Phenochart software and 
scanned from 420 nm to 720 nm using Vectra 3.1 Automated quantitative pathology imaging 
system. Three MSIs per sample was analysed using InForm analysis software. Positive cells 
were segmented and counted per 20X magnification field. 
LDE225 Treatment 
To generate high nevus count mice we crossed NOD X Cdk4R24C/R24C::Tyr-NRASQ61K 
transgenics. We topically treated the dorsal area with LDE225-DMSO (10 mg/ml, Selleck 
Chemicals) every day from P5 to P10 (with skin harvested at P10). Controls were treated with 
DMSO alone. Skin was harvested from drug treated and control groups (n=21) stained for 
Sox10 and slides digitised with an Aperio AT-Turbo Brightfield slide scanner. Sox10 positive 
nuclei count was determined using the Aperio IHC nuclear algorithm V8.001, and nuclear 
staining stratified into three intensities (1+ to 3+). We scored the number of strongly positive 
nuclei (3+) per 2 mm2 section. 
Bosentan Hydrate Treatment 
To generate nevus-susceptible mice crossed NOD mice with Cdk4R24C/R24C::Tyr-NRASQ61K 
transgenics. Pups were both injected intraperinatally with Bosentan hydrate-DMSO (10mM/1mL 
in DMSO, Selleck Chemicals) every day from P5 to P10 (skin harvested at P10). Controls were 
treated with DMSO. Skin was harvested from drug-treated and control groups (n=14). H&E-
stained slides were digitized with Aperio AT-Turbo Brightfield slide scanner, and intensity of 
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pigmented cells analysed with Aperio-V9 software. We quantitated to intensity of strongly 
positive cells. 
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Figure legends 
Figure 1. Comparison of murine and human melanocytic lesions. (a) The inner ring shows 
representative images of H&E staining of murine melanocytic lesions at each nevocyte density 
score (1-10). The outer circle shows representative images of H&E staining of corresponding 
human melanocytic lesions. Scale bars = 100 µm. (b) Distribution of 70 CC strains based on 
their nevocyte density score and histopathological diagnosis. SBN: Superficial blue nevus, DBN: 
Deep blue nevus, DPN: Deep penetrating nevus, EBN: Epithelioid blue nevus and M: 
Melanocytoma. (c) Heat map of pigmentation in megapixel per 20X field of digitized mouse skin 
from 40 pigmented CC strains bearing Cdk4::NRAS and their relevant 1-10 nevocyte density 
score. 
Figure 2. Giant congenital nevus is composed of interconnected melanocytomas. (a) 
Lesions in Cdon+/- mice. By dermoscopy blue coloration is due to dermal melanocytes (blue 
nevus). H&E shows dermal dendritic melanocytes (yellow arrow), while the white arrow shows 
dermal epithelioid melanocytes. (b) Normal telogen skin from wild type and Cdon+/- mice, 
showing ectopic pigmentation and higher density of hair follicles in wild type. (c) Visual 
appearance of dorsal surface of susceptible Cdk4::NRAS::CdonNOD/+ mouse (right), at 8 months 
of age, versus a resistant Cdk4::NRAS::Cdon+/+ (+/+ = wild type) mouse (left), at 24 months, 
with dermoscopic images of tail and dorsal skin, and H&E staining of dorsal skin. Both mice are 
hyperpigmented, but the animal carrying the CdonNOD allele exhibits a large thick giant 
congenital nevus-like lesion covering the majority of the dorsal surface. All Scale bars = 300 µm. 
(d) Large human congenital nevus. Red box shows large hyperpigmented plaque within nevus 
area. Patients provided permission for publication of their images. 
Figure 3. Upregulation of Gli in keratinocytes potentiates nevogenesis. Images of 4-plex 
fluorescent immunohistochemistry with Tyramide signal amplification using Sox10/Gli1/Gli2 
antibodies. Samples are of dorsal skin. (a-d) The magnification of images in Figure 4a-4d are 
the same. Images show susceptible Cdk4::NRAS::CdonNOD/+ mice and resistant 
Cdk4::NRAS::Cdon+/+ mice at P10 and adulthood. Yellow arrows denote melanocytoma. (e and 
f) Proportion of Gli1 and Gli2-positive cells per mm2 in dorsal skin from susceptible and resistant 
mouse strains at P10 (n=10), P21 (n=10) and adulthood (n=21), quantitated using InForm 
software (p-values calculated using two-tailed T test, ****=p<0.0001). Scale bars = 60 µm. (g) 
Human congenital nevus expressing Shh pathway components. Scale bars = 800 µm. (h) 
Sox10 staining of dorsal skin from susceptible Cdk4::NRAS::CdonNOD/+ mice treated with 
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LDE225 versus (control left panel). Red dotted line denotes superficial blue nevus. Blue arrows 
denote melanocytes located ectopically in, and at risk of escape from, the hair bulb. Graphs to 
the right show Sox10-positive nuclei counts in hair follicle bulb (i) at 40X, and the superficial 
dermis (j), at 20X magnification, of LDE225-treated mice (n=11) and controls (n=10). Cells 
quantitated using the nuclear staining algorithm of the AperioTM.  Scale bars = 60 µm. 
****=p<0.0001, **=p<0.007. 
Figure 4. Mechanism of exacerbation of nevogenesis. (a) Relative gene expression (Log 
fold change) in tamoxifen-induced versus control K14-Ptch1 and K14CREER/Rosa-SmoM2 
epidermis. Differences significant except where marked (n.s=p> 0.05). (b) Expression of Edn1 in 
P10 anagen skin from Cdk4::NRAS mice carrying the CdonNOD variant. (c) Quantitative protein 
expression analysis of Edn1 in susceptible Cdk4::NRAS::CdonNOD/+ (n=14 mice) versus a 
resistant Cdk4::NRAS::Cdon+/+ (+/+ denotes wild type at Cdon) (n=7), as measured with InForm 
software (p=value calculated using the two-tailed T test (****= p<0.0001). (d) Edn1 expression in 
adult WT versus Cdon+/- mouse skin in telogen. (e) Quantitative protein expression analysis of 
Edn1 in adult WT  (n=3) versus Cdon+/- (n=4). (**= p<0.005). (f) Images of H&E staining of 
dorsal skin from control and Bosentan (an endothelin receptor inhibitor)-treated 
Cdk4::NRAS::CdonNOD/+ mice. Yellow arrowheads indicate blue nevi. White asterisks denote 
hair bulb filled with melanocytes in control but not Bosentan-treated mice. Graphs at right show 
pigmentation level in the dermis (g), and hair follicles (h) of control (n=7) and Bosentan-treated 
Cdk4::NRAS::CdonNOD/+ mice. There was significantly more pigmentation in control skin (two-
tailed T test, **= p<0.001), ****= p<0.0001). All Scale bar = 60 µm. 
Figure 5. Model of nevus exacerbation. Proposed mechanism of action of the Cdon-Shh-
Edn1 axis, exacerbating nevogenesis. Panel to the left depicts low innate Shh signaling activity 
in Cdk4::NRAS::Cdon+/+ resistant mouse strain (Cdon+/+), where NRASQ61K is the sole driver of 
nevogenesis. This leads to the formation of blue nevi. In Cdk4::NRAS::CdonNOD/+ mice with high 
innate Shh signaling, the Shh-Edn1 axis is activated by the CdonNOD variant. Upregulation and 
secretion of Edn1 from keratinocytes activates the Ednrb-Gnaq/Gna11 complex, which in turn 
augments the effect of NRASQ61K on MAPK, resulting in the formation of melanocytoma (right 
panel). Targeting of the Cdon-Shh-Edn1 axis using Shh and endothelin pathway antagonists 
(LDE225 and Bosentan respectively) suppresses nevogenesis. 
Suppl. Figure 1. Histopathological variation of melanocytic lesions with Cdk4::NRAS 
mutation. (a) Images of H&E staining of superficial and deep blue nevus in mouse and human. 
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Nevocytes are comprised of pigmented dendritic cells having wedge shape architecture. (b) 
Images of H&E staining of mouse and human deep penetrating nevus. These lesions appear in 
deep dermis, superficial hypodermis, or adjacent to hair follicle bulb area. Pigmented balloon 
cell-like nevocytes sometimes appear in these lesions. Scale bars = 100 um. (c) Images of H&E 
staining of mouse non-bleached and bleached epithelioid blue nevus (left) and human 
epithelioid blue nevus (right). Scale bars = 400 µm. (d) Images of H&E staining of mouse non-
bleached and bleached murine melanocytoma (left) and human melanocytoma (right). These 
lesions contain 3 cell types: dendritic cells, heavily pigmented balloon cells and epithelioid cells. 
Scale bars = 400 µm.  
Supplementary Figure 2. CDON expression in non-lesional human and mouse skin IF 
staining of CDON in normal human (a) and mouse skin (b). CDON expression is mainly 
detected in the upper layer of epidermis and in the hair follicles. Scale bar = 100 µm. 
Supplementary Figure 3. SHH activity in human dermal nevus and mouse melanocytoma 
(a) Three-Plex immunofluoresence with tyramide signal amplification (3Plex-TSA) of SOX10, 
CDON and GLI1 in human dermal nevus with congenital features. CDON is mainly expressed in 
keratinocytes of epidermis, hair follicle. CDON expression and GLI1 overlap follows similar 
pattern. Scale bars = 300 µm. (b) 3Plex-TSA of adult NOD mouse melanocytoma with Sox10-
Cdon-Gli1. Murine lesion shows similar high Shh signalling. Scale bars = 100 µm.  
Supplementary Figure 4. Alopecia is observed in high Shh signalling strains (a) H&E 
images of dorsal skin from wild type and Cdon heterozygous knockout littermates. Lower 
panels, H&E images of dorsal skin from Cdk4::NRAS+CC progeny mice on nevus-resistant and 
susceptible strain backgrounds respectively. Scale bars = 300 µm. (b) Average count per strain 
of hair follicles per 1.5mm of dorsal skin (WT, n=4, susceptible strains, n=8, wt, resistant strains, 
n=8, Cdon+/-, n= 5). Statistical comparisons performed with a T-=test, ***=p<0.001, **=p<0.01, 
*=p<0.05 
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